3/17/2023 0 Comments Hemera biosciences![]() Jerry Silver, and his team through our scientific partnership with Case Western Reserve University. ![]() Brennan commented: "It has been a privilege to serve as president and CEO of Nervgen over the past three years, working hand in hand with a strong dedicated team, the company's board of directors and our scientific founder, Dr. We look forward to working with him during this transition period and wish him the best in his future endeavours." With a phase 1 safety study actively enrolling patients, multiple phase 2 clinical trials in development with anticipated readouts beginning in 2024 and a cash balance of $25-million, the largest in the company's history, Paul has helped position Nervgen to become a leading player in the emerging central nervous system repair field. "Under Paul's leadership, Nervgen has evolved from a preclinical company focused primarily on spinal cord injury to a clinical company with three active clinical development programs under way focused more broadly on repairing nervous system damage from both traumatic injuries and neurodegenerative disease. "On behalf of the board of directors and shareholders of Nervgen, I would like to thank Paul for his hard work and many contributions to Nervgen over the past three years," said Mr. Radvak received a bachelor of applied science degree from the University of British Columbia. He was a founder and the CEO of Response Biomedical, a publicly listed medical device company that he led from inception into a sales and manufacturing company. Radvak has been the CEO and director of multiple start-up companies. Radvak served as president of Nervgen from January, 2017, to June, 2018. Brennan to step down as president and chief executive officer and member of the board of directors will serve as a strategic advisor for a transition period. Rogers, member of the board of directors, appointed interim president Radvak, co-founder and executive chairman of the board, appointed interim chief executive officer The board has initiated a search for a permanent CEO. Brennan will serve as a strategic adviser to management and the board during the transition period. The board of directors has appointed current executive chairman of the board, Bill Radvak, as interim CEO and current board member Dr. ![]() Brennan will step down as president and chief executive officer and a member of the board, effective immediately. Nervgen Pharma Corp.'s board of directors and Paul Brennan have mutually agreed that Mr. NERVGEN PHARMA ANNOUNCES LEADERSHIP TRANSITION ![]() Nervgen Pharma's Brennan out as president, CEO ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |